Surf Bio is a preclinical biopharmaceutical company focused on transforming delivery of antibodies and biologics. Its Surf SnapShot technology enables ultra-high concentration formulations and subcutaneous injections, allowing rapid dosing and at-home administration for therapies in areas such as diabetes, oncology, HIV, and COVID-19. The company aims to replace traditional IV infusions with simple, standard autoinjector shots, broadening patient access to high-dose biologics. Founded in 2021 by the founders of Bigfoot Biomedical and Mode AGC, Surf Bio combines polymer-based excipients with delivery innovations to enhance stability and patient convenience, and operates globally in the biotherapeutics space.